Intercept (LOS ≥ 8 d) | −3.5400 | |
|
Intercept (LOS 3–7 d) | −1.6171 | |
|
Age (per 1-yr increments) | 0.00788 | LOS ≥ 8d: 1.01 (1.00–1.01) |
−0.00518 | LOS 3–7d: 1.00 (0.99–1.00) |
|
Male sex | 0.4534 | LOS ≥ 8d: 1.57 (1.36–1.82) |
0.1993 | LOS 3–7d: 1.22 (1.09–1.37) |
|
STEMI and NSTEMI | 0.4255 | LOS ≥ 8d: 1.53 (1.33–1.77) |
1.1155 | LOS 3–7d: 3.05 (2.75–3.39) |
|
Atrial fibrillation | 1.6758 | LOS ≥ 8d: 5.34 (4.57–6.25) |
0.5557 | LOS 3–7d: 1.74 (1.48–2.06) |
|
Atrioventricular block | 0.8276 | LOS ≥ 8d: 2.29 (1.58–3.31) |
0.3945 | LOS 3–7d: 1.48 (1.05–2.10) |
|
Cardiac arrest, VT/VF, cardiogenic shock | 1.3084 | LOS ≥ 8d: 3.70 (2.80–4.88) |
0.7964 | LOS 3–7d: 2.22 (1.71–2.88) |
|
Acute pulmonary embolism | 2.3081 | LOS≥ 8d: 10.06 (3.08–32.85) |
0.5064 | LOS 3–7d: 1.66 (0.37–7.49) |
|
Acute respiratory failure | 3.1540 | LOS ≥ 8d: 23.43 (6.48–84.78) |
0.9927 | LOS 3–7d: 2.70 (0.58–12.57) |
|
Acute kidney failure | 1.5269 | LOS ≥ 8d: 4.60 (2.93–7.24) |
0.5205 | LOS 3–7d: 1.68 (1.01–2.82) |
|
Pulmonary hypertension | 0.5935 | LOS ≥ 8d: 1.81 (1.26–2.60) |
0.3431 | LOS 3–7d: 1.41 (0.97–2.06) |
|
Implantable cardioverter-defibrillator | 0.4965 | LOS ≥ 8d: 1.64 (0.92–2.94) |
1.1387 | LOS 3–7d: 3.12 (1.91–5.10) |
|
Heart failure | 0.9782 | LOS ≥ 8d: 2.66 (1.93–3.66) |
0.6085 | LOS 3–7d: 1.84 (1.34–2.52) |
|
Peripheral arterial disease and cerebrovascular disease | 0.4823 | LOS ≥ 8d: 1.62 (1.37–1.92) |
−0.1119 | LOS 3–7d: 0.89 (0.76–1.05) |
|
Chronic pulmonary disease | 0.4860 | LOS ≥ 8d: 1.63 (1.34–1.98) |
0.2489 | LOS 3–7d: 1.28 (1.08–1.52) |
|
Hypertension | 0.4249 | LOS ≥ 8d: 1.53 (1.33–1.76) |
0.2842 | LOS 3–7d: 1.33 (1.20–1.48) |
|
Chronic kidney disease | −0.1732 | LOS ≥ 8d: 0.84 (0.68–1.04) |
−0.4072 | LOS 3–7d: 0.67 (0.55–0.81) |
|
Neurological disorders | 1.0158 | LOS ≥ 8d: 2.76 (1.77–4.32) |
−0.1521 | LOS 3–7d: 0.86 (0.52–1.42) |
|
Coagulopathy | 1.1773 | LOS ≥ 8d: 3.25 (1.83–5.76) |
0.5014 | LOS 3–7d: 1.65 (0.93–2.93) |
Akaike Information Criterion | 15 880 |